IDH1 and astrocytoma (excluding glioblastoma): Cryan et al also demonstrated a limitation of traditional IDH1 antibody testing in terms of the sensitivity of the applied antibody.[11] Moreover, it was proven that survival benefits associated with surgical strategies differ based on the IDH1 genotype in malignant astrocytomas.[12] Therefore, a noninvasive method for preoperative prediction of the IDH genotype is important for surgical planning and research in understanding the biology of gliomas.